Celcuity’s (CELC) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Celcuity (NASDAQ:CELC) in a report issued on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $122.00 price objective on the stock.

Several other brokerages also recently weighed in on CELC. Wells Fargo & Company initiated coverage on Celcuity in a research note on Friday, December 12th. They issued an “overweight” rating and a $126.00 target price on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $94.00 price target (up from $77.00) on shares of Celcuity in a report on Monday, November 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Jefferies Financial Group boosted their price objective on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Finally, Wolfe Research restated an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a research report on Thursday, March 12th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Celcuity has an average rating of “Moderate Buy” and a consensus target price of $108.63.

Celcuity Stock Performance

NASDAQ:CELC opened at $114.11 on Tuesday. Celcuity has a 52 week low of $7.57 and a 52 week high of $120.32. The company has a fifty day simple moving average of $109.20 and a two-hundred day simple moving average of $88.22. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. The company has a market cap of $5.28 billion, a price-to-earnings ratio of -31.09 and a beta of 0.38.

Insider Buying and Selling at Celcuity

In related news, Director David Dalvey sold 20,000 shares of Celcuity stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total value of $2,400,600.00. Following the sale, the director directly owned 90,000 shares in the company, valued at $10,802,700. This trade represents a 18.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.78% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Celcuity

A number of hedge funds have recently made changes to their positions in CELC. Seven Fleet Capital Management LP acquired a new position in Celcuity during the 4th quarter worth $783,000. Invesco Ltd. grew its position in Celcuity by 4.9% in the 4th quarter. Invesco Ltd. now owns 147,938 shares of the company’s stock valued at $14,755,000 after buying an additional 6,928 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Celcuity in the 4th quarter valued at about $376,000. KVP Capital Advisors LP acquired a new position in Celcuity during the 4th quarter valued at about $399,000. Finally, XTX Topco Ltd increased its stake in Celcuity by 16.3% during the 4th quarter. XTX Topco Ltd now owns 13,275 shares of the company’s stock valued at $1,324,000 after buying an additional 1,862 shares during the period. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.